Seeking Alpha

pslice84

pslice84
Send Message
View as an RSS Feed
View pslice84's Comments BY TICKER:
Latest  |  Highest rated
  • Why Retrophin Makes Me Uncomfortable [View article]
    Suggest you do some actual research.

    1- Cash quoted in the article is entirely inaccurate. They raised ~$40M in January.

    "On January 9, 2014, we completed a public offering of 4,705,882 shares of common stock at a price of $8.50 per share. We received net proceeds from the offering of $37,399,997, after deducting the underwriting discount and other estimated offering expenses of $2,600,000. Our common stock is listed on the Nasdaq Global Market under the symbol “RTRX.”"

    1b - You are backing out the full amount of the Manchester deal without actually looking at the full details.

    "Under the terms of the agreement, the Company paid $29.5 million upon closing, of which $3.2 million was paid by Retrophin Therapeutics International LLC, a newly formed indirect wholly owned subsidiary, for rights of product sales outside of the United States. The Company entered into a promissory note with Manchester principals for $33 million to be paid in three equal installments of $11 million within three, six, and nine months after closing. Additional contingent payments will be made based on product sales. The Company expects to raise additional funds through a public equity offering, a private equity offering, and/or debt financing to satisfy its short term obligations."

    2- Just from looking at your articles, it's pretty clear your familiarity with biotechs is close to zero.

    3- Smart investors average UP on great companies.
    Apr 9 09:47 PM | Likes Like |Link to Comment
  • Newlink Genetics' Pancreatic Cancer Vaccine Likely To Disappoint Investors In 2013 [View article]
    it is concerning that none of the major pancreatic KOLs are participating in the study.
    Jun 26 09:01 PM | Likes Like |Link to Comment
  • Alnylam: Further Evidence That The Stock Is Overvalued [View article]
    @SeekingValue - You also fail to mention what the money means to each party. ISIS really needs the money, ALNY did not. However, Alnylam management/team are quite incompetent when it comes to doing actual drug development, they need Genzyme to show them the ropes.

    Alnylam is a wildly speculative stock.
    Nov 20 11:02 AM | Likes Like |Link to Comment
  • More Uncertainty Ahead For Threshold [View article]
    When drugs have overlapping toxicities, it is typically not going to be possible to combine them at therapeutic doses.

    @ TruffelPig - After reviewing your previous comments, it's pretty clear that you are endlessly biased on all your stocks. Maybe take a step back. Threshold is behind both ZIOP (by > 1 year) and CELG (by > 2.5 years) with a drug that doesnt look better than either.
    Nov 15 03:24 PM | Likes Like |Link to Comment
  • Alnylam: No Approved Drugs, No Promising Candidates, No Justification For $1 Billion Valuation [View article]
    Nice valuation short call. It also seems possible Alnylam won't beat GSK/ISIS to market in TTR either. Following the news that ISIS/GSK will run a pivotal Phase 2/3 does not bode well for ALNY.
    Nov 15 03:14 PM | Likes Like |Link to Comment
  • Could It Be An 'Alzheimer's Bonanza'? [View article]
    From this article, it is easy to tell no one at your publication understand Alzheimers or how to read data releases.
    Oct 25 05:34 AM | 1 Like Like |Link to Comment
  • Oncolytics Sharply Overvalued Following REO 018 Trial Failure [View article]
    I couldnt agree more with this article. ONCY management is utterly incompetent.
    Sep 17 10:25 AM | 3 Likes Like |Link to Comment
  • Navidea Biopharmaceutical Undervalued Approaching FDA Decision [View article]
    CRL today!! Ha.
    Sep 11 04:02 AM | 1 Like Like |Link to Comment
  • Knight Capital's Rescue Deal - A Lesson For Biotech Investors [View article]
    "The company estimates worldwide revenue from Lymphoseek will be around $450 million per year."

    Stop dancing around this. Do you believe it? Probably not. Whatever boosts the share price for you.

    Also, the company has been dealing with CMC issues for over 5 years and still no fix. Nice CRL today.
    Sep 11 04:02 AM | Likes Like |Link to Comment
  • Sarepta Therapeutics: Stock Rising Too Far, Too Fast? [View article]
    I respectfully suggest Mr. David Zanoni stick to writing about non-biotech, since after looking thru some of his articles on them, he clearly has little expertise in the area.

    You're trying to make a technical short call on a stock whose fundamentals have risen dramatically because of their pipeline. This is how biotech works. Technicals are BS in biotech. PCYC and MDVN kept going straight up regardless of some of the stupid commentary people made on the underlying technicals.
    Sep 3 02:56 AM | 2 Likes Like |Link to Comment
  • Peregrine: Bavi Results Are Overhyped And Inconclusive [View article]
    Failed studies have made the Best of ASCO list. Not every late-breaking presentation has to be good data. Need to learn from mistakes...
    Aug 22 02:35 PM | Likes Like |Link to Comment
  • Several Catalysts Are Near For Peregrine Pharmaceuticals [View article]
    I dont know how you could possibly read what I wrote and think it supports PPHM.

    (1) Bavi likely has little to no effect on KRAS given its MoA; it does not target pathway mutations.

    (2) Given DTIC's performance in one of the worst mutational groups, you expect much better performance in the portion of patients without KRAS aka OS > 6 months by a lot. Consider a recent large Phase 3 study that showed OS in 2L NSCLC of 10 months! Although a bit high compared to some previously run small Phase 2's, it is a large randomized Phase 3 study

    Herbst 2010 ("Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial")

    "However, in the present study, the median overall survival of 10 months for patients receiving placebo plus docetaxel is longer than that reported in the earlier studies. This difference might be explained by differences in the availability or use of first-line and post-progression therapies, as well as general improvements in standards of care over time."

    Hanna 2004 - 7.9 months
    http://bit.ly/Pwt26S

    Kim 2008 - 8 months
    http://bit.ly/P29m71

    So yeah, seeing < 6 months means something is up.
    Aug 17 02:26 AM | Likes Like |Link to Comment
  • Several Catalysts Are Near For Peregrine Pharmaceuticals [View article]
    OS result of <6-month in docetaxel arm is way too short to be credible.

    - ARRY recently reported OS in 2L NSCLC (stage IIIB and IV) who are KRAS positive: Overall survival was longer for selumetinib in combination with docetaxel compared to docetaxel alone (9.4 mo vs 5.2 mo; 56 events, median follow-up 219 days).

    KRAS positive patients have significantly worse prognosis, so there is likely something wrong with the randomization or baseline levels of patients are not equal across arms.
    Aug 16 03:49 PM | 2 Likes Like |Link to Comment
  • Several Catalysts Are Near For Peregrine Pharmaceuticals [View article]
    Some more red flags to make one cautious

    - Trial unblinded in May and failed ORR/PFS. No way around this; no p-values or Hazard Ratios reported. Now the company is touting an unofficial endpoint in OS.

    - Another red flag with touting such a purportedly large OS benefit is why haven't placebo patients switched over Bavi after unblinding?

    Maybe PPHM got lucky, but this is risky data to hold through IMO.
    Aug 16 02:40 PM | 3 Likes Like |Link to Comment
  • Several Catalysts Are Near For Peregrine Pharmaceuticals [View article]
    (1) How did you leave out the fact that the top-line data in 2nd line NSCLC FAILED??????!!!!! No HR's or p-values listed are highly indicative of a failed study, however PPHM isn't an honest company, which is why they didn't report them.

    http://bit.ly/P9Ugz3

    (2) How did you forget to mention the study failed in 1st line NSCLC? No benefit, it's just a placebo based on these data.

    "Based on independent central imaging reads, patients demonstrated a current median PFS estimate of 6.7 months for the bavituximab-containing arm and 6.4 months for the chemotherapy-only arm. Peregrine expects to report median overall survival (OS) from this trial in the second half of 2012. "

    http://bit.ly/Rk2KH4

    (3) A quote from you: "As of July, 2012, the majority of patients were still alive with Bavituximab, so the MOS wasn't able to be calculated yet. That's an extra two to three months that the patients have lived their lives, which is significant and the biggest reason why the stock has gone on such an epic run since June."

    This couldn't be farther from the truth, just sickeningly speculative. ARRY reported OS almost 2X the SOC in their trial and it only gave a p-value of 0.2. You are disregarding how the survival curves look and how small this trial actually is. Given how small this trial is, I am willing to bet the OS results will not be statistically significant as well.

    (4) Given the large number of ex-US clinical sites for this trial, hard to believe any results will hold up in another trial. Russia, India, Ukraine.

    http://1.usa.gov/N6eCot;rank=6&amp;show_l...
    Aug 16 11:43 AM | 2 Likes Like |Link to Comment
COMMENTS STATS
308 Comments
222 Likes